Answers are grounded in this paper and cite their sources.
Retrospective registry analysis reveals changes in pancreatic enzyme replacement therapy prescriptions following ivacaftor licensing, highlighting modulated gastrointestinal function.
Relieving gastrointestinal symptoms is a research priority in cystic fibrosis. Emerging evidence highlights effects of cystic fibrosis transmembrane conductance regulator (CFTR) modulators on gastrointestinal function, including pancreatic sufficiency. This study explores ivacaftor licensing and treatment on recorded pancreatic enzyme replacement therapy (PERT) prescription in the US and UK CF registries.
No takes yet. Share an insight, caveat, or question.
Calthorpe et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: